How can patients’ trajectories inform the co-design of an integrated care network for people living with Parkinson’s Disease?
Objective: The aim of this study is to provide a better understanding of how patients’ experience could inform the design of an integrated care network…Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon
Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…Hyperkinetic Movement Disorders after Thalamic Lesions
Objective: To describe delayed hyperkinetic movement disorder after a thalamic lesion. Background: Lesions in the basal ganglia circuit can cause abnormal movement disorders. After thalamic…Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Reversible MIBG Abnormalities in Subjects at Risk for Synucleinopathy: 12 months data
Objective: To investigate the long-term effects of the adrenergic blocker carvedilol on I-MIBG myocardial uptake in subjects with REM sleep behavior disorder (RBD) and other…Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinson’s Disease- A Pilot study.
Objective: To compare improvement in tremor at 12 weeks with Zonisamide given in a dose of 25 mg along with other ant- parkinsonian drugs as…Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 132
- Next Page »